REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.03 Billion KRW | -76.12% |
| 2022 | 7.4 Billion KRW | 29.19% |
| 2021 | 5.73 Billion KRW | 38.18% |
| 2020 | 4.14 Billion KRW | -47.46% |
| 2019 | 7.89 Billion KRW | 221.09% |
| 2018 | 2.45 Billion KRW | -84.63% |
| 2017 | 16 Billion KRW | 13.77% |
| 2016 | 14.06 Billion KRW | -29.1% |
| 2015 | 19.83 Billion KRW | 18.62% |
| 2014 | 16.72 Billion KRW | -4.06% |
| 2013 | 17.43 Billion KRW | -17.87% |
| 2012 | 21.22 Billion KRW | -12.89% |
| 2011 | 24.36 Billion KRW | -9.76% |
| 2010 | 27 Billion KRW | 30.61% |
| 2009 | 20.67 Billion KRW | 56.45% |
| 2008 | 13.21 Billion KRW | 35.0% |
| 2007 | 9.78 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 1 Billion KRW | -38.31% |
| 2024 Q2 | -69.27 Million KRW | -85.77% |
| 2023 Q4 | 1.63 Billion KRW | 1775.75% |
| 2023 Q2 | 2.65 Billion KRW | 12.9% |
| 2023 Q3 | 87.05 Million KRW | -96.72% |
| 2023 FY | 1.76 Billion KRW | -76.12% |
| 2023 Q1 | 2.35 Billion KRW | 14.26% |
| 2022 Q4 | 2.06 Billion KRW | -28.43% |
| 2022 Q3 | 2.87 Billion KRW | 1517.52% |
| 2022 Q1 | 2.95 Billion KRW | 47.46% |
| 2022 FY | 7.4 Billion KRW | 29.19% |
| 2022 Q2 | -203.08 Million KRW | -106.87% |
| 2021 Q3 | 49.93 Million KRW | -74.94% |
| 2021 Q1 | 1.48 Billion KRW | -46.29% |
| 2021 FY | 5.73 Billion KRW | 38.18% |
| 2021 Q2 | 199.23 Million KRW | -86.58% |
| 2021 Q4 | 2 Billion KRW | 3917.11% |
| 2020 Q3 | 719.1 Million KRW | -15.6% |
| 2020 Q2 | 852 Million KRW | 561.21% |
| 2020 Q1 | -184.73 Million KRW | -118.92% |
| 2020 FY | 4.14 Billion KRW | -47.46% |
| 2020 Q4 | 2.76 Billion KRW | 284.27% |
| 2019 Q2 | 1.49 Billion KRW | -49.15% |
| 2019 Q4 | 976.16 Million KRW | -60.55% |
| 2019 FY | 7.89 Billion KRW | 221.09% |
| 2019 Q1 | 2.94 Billion KRW | 160.96% |
| 2019 Q3 | 2.47 Billion KRW | 65.06% |
| 2018 Q3 | 1.47 Billion KRW | 1.4% |
| 2018 FY | 2.45 Billion KRW | -84.63% |
| 2018 Q4 | -4.83 Billion KRW | -428.69% |
| 2018 Q2 | 1.45 Billion KRW | -66.82% |
| 2018 Q1 | 4.37 Billion KRW | 218.89% |
| 2017 FY | 16 Billion KRW | 13.77% |
| 2017 Q4 | 1.37 Billion KRW | -68.77% |
| 2017 Q3 | 4.39 Billion KRW | 6.83% |
| 2017 Q2 | 4.11 Billion KRW | -32.3% |
| 2017 Q1 | 6.07 Billion KRW | 135.58% |
| 2016 Q3 | 3.21 Billion KRW | 4.29% |
| 2016 FY | 14.06 Billion KRW | -29.1% |
| 2016 Q4 | 2.57 Billion KRW | -19.77% |
| 2016 Q2 | 3.08 Billion KRW | -40.67% |
| 2016 Q1 | 5.19 Billion KRW | -16.13% |
| 2015 Q3 | 4.76 Billion KRW | 17.56% |
| 2015 Q4 | 6.19 Billion KRW | 29.95% |
| 2015 Q2 | 4.05 Billion KRW | -16.03% |
| 2015 Q1 | 4.82 Billion KRW | 49.61% |
| 2015 FY | 19.83 Billion KRW | 18.62% |
| 2014 Q4 | 3.22 Billion KRW | -14.56% |
| 2014 Q2 | 4.71 Billion KRW | -5.73% |
| 2014 Q1 | 5 Billion KRW | 19.73% |
| 2014 FY | 16.72 Billion KRW | -4.06% |
| 2014 Q3 | 3.77 Billion KRW | -19.94% |
| 2013 Q1 | 3.09 Billion KRW | -42.93% |
| 2013 Q2 | 5.7 Billion KRW | 84.15% |
| 2013 Q4 | 4.17 Billion KRW | -6.19% |
| 2013 Q3 | 4.45 Billion KRW | -21.88% |
| 2013 FY | 17.43 Billion KRW | -17.87% |
| 2012 FY | 21.22 Billion KRW | -12.89% |
| 2012 Q4 | 5.42 Billion KRW | -12.25% |
| 2012 Q3 | 6.18 Billion KRW | 3.09% |
| 2012 Q2 | 5.99 Billion KRW | 101.64% |
| 2012 Q1 | 2.97 Billion KRW | -29.78% |
| 2011 Q2 | 5.8 Billion KRW | -32.6% |
| 2011 Q1 | 8.61 Billion KRW | 14.93% |
| 2011 Q3 | 5.7 Billion KRW | -1.72% |
| 2011 Q4 | 4.23 Billion KRW | -25.79% |
| 2011 FY | 24.36 Billion KRW | -9.76% |
| 2010 Q3 | 7.4 Billion KRW | 12.61% |
| 2010 FY | 27 Billion KRW | 30.61% |
| 2010 Q2 | 6.57 Billion KRW | 0.0% |
| 2010 Q4 | 7.49 Billion KRW | 1.18% |
| 2009 FY | 20.67 Billion KRW | 56.45% |
| 2008 FY | 13.21 Billion KRW | 35.0% |
| 2007 FY | 9.78 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1006.507% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 94.753% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 105.07% |
| HANDOK Inc. | 12.57 Billion KRW | 67.933% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 302.782% |
| Yuhan Corporation | 74.56 Billion KRW | 94.59% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | 63.916% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 122.356% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 98.206% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -31.988% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 71.892% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -576.326% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -318.528% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 85.078% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1006.507% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 152.006% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 105.766% |
| JW Holdings Corporation | 143.66 Billion KRW | 97.192% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 107.551% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 98.364% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 95.979% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 108.511% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | 41.769% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | 37.666% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | 53.803% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -1006.507% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 91.729% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 96.976% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 95.979% |
| Yuhan Corporation | 74.56 Billion KRW | 94.59% |
| Jeil Pharma Holdings Inc | 20.92 Billion KRW | 80.719% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -29.391% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 90.618% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 95.979% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | 80.309% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 92.659% |
| CKD Bio Corp. | -20.15 Billion KRW | 120.016% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 87.486% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 84.058% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 87.598% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 108.511% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 87.831% |
| Boryung Corporation | 68.26 Billion KRW | 94.091% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 110.757% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | 71.892% |
| JW Lifescience Corporation | 32.09 Billion KRW | 87.431% |